Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
Add more filters










Publication year range
1.
J Eur Acad Dermatol Venereol ; 38(1): 182-185, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37593888

ABSTRACT

BACKGROUND: Toxic epidermal necrolysis (TEN) is a severe life-threatening drug eruption with rapid evolution. A fast histologic differentiation between TEN and clinically similarly looking staphylococcal scalded skin syndrome is of vital importance for relevant treatment decision. The recently developed ex vivo confocal laser scanning microscopy (CLSM) offers innovative and extremely fast histological visualization of fresh tissue specimens. OBJECTIVE: To assess the diagnostic efficacy of ex vivo CLSM in comparison with standard histopathology for TEN. METHODS: We performed side-by-side comparison of TEN specimens analysed with ex vivo CLSM and haematoxylin and eosin staining. Analysis focused on typical histopathological features of TEN, including epidermal cleavage in the basal layer and confluent epidermal necrosis. We retrospectively assessed the diagnostic performance of ex vivo CLSM for TEN in clinically confirmed cases. RESULTS: We report substantial agreement between ex vivo CLSM and classical histology for the detection of subepidermal cleavage and confluent epidermal necrosis. When considering full-thickness epidermal loss, epidermal cleavage in the basal layer showed the highest diagnostic performance, reaching 87.5% sensitivity and 100% specificity. CONCLUSION: Based on our data, ex vivo CSLM appears as a rapid, resource-optimizing, and reliable approach for morphological TEN emergency screening on fresh skin samples.


Subject(s)
Stevens-Johnson Syndrome , Humans , Stevens-Johnson Syndrome/diagnosis , Stevens-Johnson Syndrome/pathology , Retrospective Studies , Skin/pathology , Microscopy, Confocal , Necrosis
2.
Expert Opin Biol Ther ; 23(12): 1307-1315, 2023.
Article in English | MEDLINE | ID: mdl-38108300

ABSTRACT

BACKGROUND: Tralokinumab is a human monoclonal antibody targeting interleukin-13 that is approved for the treatment of moderate-severe atopic dermatitis. Studies analyzing the efficacy and safety of tralokinumab in a real-world setting are scarce. RESEARCH DESIGN AND METHODS: A European, multicentric, real-world, retrospective cohort study was defined to assess the effectiveness and safeness profile of tralokinumab, investigating the achievement of pre-specified treatment goals; and to detect potential differences in terms of effectiveness and safeness across some selected patient subcohorts. RESULTS: A total of 194 adult patients were included in this study. A significant improvement in physician-assessed disease severity was detected at each follow-up visit as compared with baseline and similar trend was observed for patient-reported outcomes and quality of life. No meaningful difference in effectiveness was found when considering patient age (<65 versus ≥65 years), neither dissecting patient cohort in dupilumab-naive vs dupilumab-treated subjects. Among tralokinumab-treated patients, 88% achieved at least one currently identified real-world therapeutic goal at week 16. CONCLUSIONS: This retrospective multicenter study confirmed the effectiveness and safeness of tralokinumab throughout 32 weeks of observation, showing the achievement of therapeutic goals identified in both trial and real-world settings in a large proportion of tralokinumab-treated patients.


Subject(s)
Dermatitis, Atopic , Adult , Humans , Aged , Dermatitis, Atopic/diagnosis , Dermatitis, Atopic/drug therapy , Retrospective Studies , Goals , Cohort Studies , Quality of Life , Treatment Outcome , Antibodies, Monoclonal/adverse effects , Severity of Illness Index , Double-Blind Method
3.
J Eur Acad Dermatol Venereol ; 35(2): 387-395, 2021 Feb.
Article in English | MEDLINE | ID: mdl-32569440

ABSTRACT

BACKGROUND: Melanoma is the leading cause of skin cancer-related deaths worldwide. While there have been significant improvements in the treatment of advanced melanoma in the past decade, biomarker development lagged behind. OBJECTIVES: The majority of liquid biopsy biomarkers rely on the analyses of oncogenic mutations; however, about 20% of melanoma patients are wild type. Therefore, validation of universal predictive and prognostic biomarkers is urgently needed. METHODS: We analysed plasma samples in a discovery cohort (n = 20) and expansion cohort (n = 166) of metastatic melanoma patients and healthy donors (n = 116). Total plasma circulating cell-free DNA (cfDNA) concentrations were measured on the Qubit® platform using assays for single-(ss) and double (ds)-stranded DNA, DNA spectrophotometry and RNase P qPCR. We explored the diagnostic, predictive and prognostic potential of cfDNA concentration by bio-statistical methods and established a cfDNA threshold for risk stratification. RESULTS: Our selected best method was Qubit® dsDNA assay which quantified higher plasma cfDNA concentrations in melanoma patients than in healthy controls (AUC 72%). Measurement of baseline cfDNA concentration revealed that high cfDNA was associated with presence of metastases and higher AJCC stage (P < 0.05). Furthermore, high baseline cfDNA was an indicator of shorter overall survival in patients with oncogenic mutations (HR 2.12, P = 0.0008), and in wild-type patients (HR 5.55, P < 0.0001). CONCLUSIONS: We provide evidence that total cfDNA can be used as a biomarker for melanoma irrespective of the tumour genotype and can provide information on tumour load, risk of progression and risk of death.


Subject(s)
Cell-Free Nucleic Acids , Melanoma , Biomarkers, Tumor/genetics , Humans , Melanoma/genetics , Prognosis , Tumor Burden
4.
Ann Oncol ; 30(7): 1154-1161, 2019 07 01.
Article in English | MEDLINE | ID: mdl-30923820

ABSTRACT

BACKGROUND: Programmed cell death protein 1 (PD-1) blocking monoclonal antibodies improve the overall survival of patients with advanced melanoma but the optimal duration of treatment has not been established. PATIENTS AND METHODS: This academic real-world cohort study investigated the outcome of 185 advanced melanoma patients who electively discontinued anti-PD-1 therapy with pembrolizumab (N = 167) or nivolumab (N = 18) in the absence of disease progression (PD) or treatment limiting toxicity (TLT) at 14 medical centres across Europe and Australia. RESULTS: Median time on treatment was 12 months (range 0.7-43). The best objective tumour response at the time of treatment discontinuation was complete response (CR) in 117 (63%) patients, partial response (PR) in 44 (24%) patients and stable disease (SD) in 16 (9%) patients; 8 (4%) patients had no evaluable disease (NE). After a median follow-up of 18 months (range 0.7-48) after treatment discontinuation, 78% of patients remained free of progression. Median time to progression was 12 months (range 2-23). PD was less frequent in patients with CR (14%) compared with patients with PR (32%) and SD (50%). Six out of 19 (32%) patients who were retreated with an anti-PD-1 at the time of PD obtained a new antitumour response. CONCLUSIONS: In this real-world cohort of advanced melanoma patients discontinuing anti-PD-1 therapy in the absence of TLT or PD, the duration of anti-PD-1 therapy was shorter when compared with clinical trials. In patients obtaining a CR, and being treated for >6 months, the risk of relapse after treatment discontinuation was low. Patients achieving a PR or SD as best tumour response were at higher risk for progression after discontinuing therapy, and defining optimal treatment duration in such patients deserves further study. Retreatment with an anti-PD-1 at the time of progression may lead to renewed antitumour activity in some patients. CLINICAL TRIAL REGISTRATION: NCT02673970 (https://clinicaltrials.gov/ct2/show/NCT02673970?cond=melanoma&cntry=BE&city=Jette&rank=3).


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Melanoma/drug therapy , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Skin Neoplasms/drug therapy , Substance Withdrawal Syndrome/etiology , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal, Humanized/administration & dosage , Cohort Studies , Disease Progression , Female , Follow-Up Studies , Humans , Male , Melanoma/mortality , Melanoma/pathology , Middle Aged , Nivolumab/administration & dosage , Prognosis , Prospective Studies , Retrospective Studies , Skin Neoplasms/mortality , Skin Neoplasms/pathology , Survival Rate
6.
Leukemia ; 19(12): 2273-80, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16304575

ABSTRACT

We have analyzed the clonotype composition of CD8+ T cells following nonmyeloablative (NMA) conditioning and hematopoietic cell transplantation (HCT), of patients with chronic lymphocytic leukemia (CLL). Consecutive analyses of blood samples taken up to 2 years following HCT, demonstrated that CD8+ T-cell clonality was highly dynamic in the early phases after HCT, but became more stable after 4-5 months. Moreover, donor lymphocyte infusion (DLI) given for disease progression in one of the patients led to establishment of recurrent as well as new T-cell clonotypes. This coincided with disease remission, strongly suggesting that these T cells were engaged with anti-CLL cytotoxicity. To examine the functional capacity of stable clonally expanded T cells after HCT, CD8+ T cells isolated post-transplant from the recipients were stimulated ex vivo with CLL cells and subsequently analyzed by FACS for surface expression of the marker for cytotoxic activity, CD107a. Stimulation with CLL cells indeed led to surface expression of CD107a, and clonotype analyses of sorted cells demonstrated that CD107a positive T cells were stably expanded following HCT. Our data suggest that clonally expanded CD8+ T-cell clones participate in the ongoing T-cell response against CLL cells following HCT with NMA conditioning.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Cell Proliferation , Clone Cells , Cytotoxicity, Immunologic , Hematopoietic Stem Cell Transplantation , Humans , Immunity , Longitudinal Studies , Lymphocyte Transfusion , Lysosomal-Associated Membrane Protein 1/analysis , Male , Middle Aged , Transplantation Conditioning/methods , Treatment Outcome
7.
Eur J Immunol ; 31(1): 250-8, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11265641

ABSTRACT

Immunity to tumors relies on recirculating antigen-specific T cells. Whilst induction of antigen-specific T cells by immunotherapy has been convincingly proven, direct evidence for recirculation of such cells is still lacking. Here, employing a recently established in situ immunotherapy model for murine melanoma we directly demonstrate the redistribution of clonally expanded T cells. In this model IL-2 is targeted to the tumor microenvironment by means of specific antibody-IL-2 fusion proteins resulting in the expansion of T cells. The therapeutic effect of the fusion protein is not restricted to tumors expressing the targeted antigen, but extends to antigen negative variants of the tumor if present in the same animal. Analysis of the T cell infiltrate by quantitative reverse transcription-PCR revealed the presence of highly expressed TCR BV regions in both tumor variants. TCR clonotype mapping revealed that the high expressions of these regions were caused by clonal expansions and, notably, that these specific clonotypic TCR transcripts were identical in both tumors. Thus, T cell clones activated locally by targeted IL-2 therapy recirculate and mediate eradication of distant tumor sites not subjected to in situ cytokine therapy.


Subject(s)
Antibodies/therapeutic use , Interleukin-2/therapeutic use , Melanoma, Experimental/therapy , T-Lymphocytes/immunology , Amino Acid Sequence , Animals , Base Sequence , Humans , Melanoma, Experimental/immunology , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Receptors, Antigen, T-Cell/genetics , Recombinant Fusion Proteins/therapeutic use , Reverse Transcriptase Polymerase Chain Reaction , Tumor Cells, Cultured
8.
Cancer Immunol Immunother ; 49(8): 426-32, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11043849

ABSTRACT

B16 is a murine melanoma of C57B1/6 origin, which rapidly develops as a tumor when inoculated into syngeneic immunocompetent hosts. Nevertheless, B16 tumors are considered to be immunogenic since tumor regression can be induced by means of immunotherapeutic intervention. Furthermore, B16 melanoma cells express several melanoma-associated antigens that may serve as targets for autologous T cells. To study the in vivo T cell response against B16, with particular emphasis on diversity and systemic involvement, we examined the spectra of T cell clonotypes in coexisting B16 melanoma lesions in C57B1/6 mice. Three tumors from each animal (n = 8) were examined for the presence of clonotypic T cells using the highly sensitive T cell receptor (TCR) clonotype mapping technology. Systematic analysis of the TCRB variable regions 1-16 revealed from 19 to more than 30 clonotypic TCR transcripts in each tumor. To study intra- and inter-individual variations in the T cell response further, more than 600 clono-typic TCR transcripts were compared for sequence identity. Overall, approximately 2% of the T cell clonotypes were detected in more than one tumor from the same animal. Furthermore, none of the detected clonotypes was present in more than one animal, arguing against recurrent or "public" T cell responses against B16 melanoma. Our data strongly suggest that anti-melanoma T cell responses in this murine model encompass mainly localized T cells, and that systemic involvement is limited.


Subject(s)
Melanoma, Experimental/metabolism , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Animals , Electrophoresis , Humans , Lymphocytes, Tumor-Infiltrating/immunology , Lymphocytes, Tumor-Infiltrating/metabolism , Melanoma, Experimental/immunology , Mice , Mice, Inbred C57BL , Neoplasm Transplantation , Phenotype , Receptors, Antigen, T-Cell/immunology , Receptors, Antigen, T-Cell/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Skin/immunology , Skin/metabolism , Spleen/immunology , Spleen/metabolism , Tumor Cells, Cultured
9.
Clin Immunol ; 96(2): 94-9, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10900156

ABSTRACT

Melanoma is generally accepted as being an antigenic tumor capable of eliciting T-cell responses that, however, in most cases are inadequate to control tumor growth. Tumor-infiltrating lymphocytes (TIL) in melanoma lesions comprise clonotypic T cells, indicating the in situ recognition of melanoma-associated peptide epitopes. Cultured TIL have been studied in order to unveil characteristics of TIL and the interactions of TIL and melanoma cells. Whether in vitro cultured TIL mirrors the in situ situation has, however, been questioned. In the present study we have taken advantage of T-cell receptor clonotype mapping methodology to conduct a full and detailed analysis of the T-cell clonotypes in melanoma lesions and in corresponding lines of TIL established in vitro. All melanoma lesions and the corresponding TIL cultures comprised high numbers of T-cell clonotypes, typically in the range of 40 to more than 60. The subsequent comparison of T-cell clonotypes present in the original lesions and in the corresponding T-cell lines established in vitro demonstrated that a very limited number of the T-cell clonotypes established in vitro are identical to the T-cell clonotypes expanded in situ. These results demonstrate that in situ T-cell clonotypes in melanoma are not readily expanded in vitro and that the majority of T-cell clonotypes present in cultured TIL are not present in situ.


Subject(s)
Clone Cells/cytology , Lymphocytes, Tumor-Infiltrating/cytology , Melanoma/pathology , Cell Count , Cell Separation , Cells, Cultured , Electrophoresis, Polyacrylamide Gel/methods , Flow Cytometry , Humans , Protein Denaturation , T-Lymphocytes/cytology
10.
J Immunol ; 163(1): 443-7, 1999 Jul 01.
Article in English | MEDLINE | ID: mdl-10384147

ABSTRACT

It is well established that melanoma cells express Ags that are recognized by autologous T cells in vitro. Tumor-infiltrating lymphocytes in situ comprise clonotypic T cells, suggesting that their expansion is driven by Ag stimulation. Still, little is known about the detailed characteristics of the in situ T cell response. In the present study, we scrutinized this response by analyzing multiple metastatic lesions for the presence of clonotypic T cells. This approach was chosen to distinguish whether the clonal T cell expansion occurs as a systemic or localized phenomenon. TCR clonotype mapping of six s.c. metastases from two patients revealed the presence of multiple (from 40 to >60) clonotypic T cells in all lesions. Clonotypic T cells were present in TCR beta-variable regions expressed both at high and low levels. Comparison of the T cell clonotypes present in different lesions from individual patients demonstrated that, in general, clonotypes were exclusively detected in a single lesion. Hence, anti-melanoma T cell responses are much more heterogeneous than previously anticipated and accommodate a predominance of strictly localized T cell clonotypes.


Subject(s)
Melanoma/immunology , T-Lymphocyte Subsets/immunology , Antigens, Neoplasm , Biomarkers, Tumor/biosynthesis , Cell Differentiation/immunology , Clone Cells , Electrophoresis, Polyacrylamide Gel , Humans , Lymphocyte Count , Lymphocytes, Tumor-Infiltrating/immunology , Lymphocytes, Tumor-Infiltrating/metabolism , Melanoma/metabolism , Melanoma-Specific Antigens , Neoplasm Proteins/biosynthesis , Receptors, Antigen, T-Cell, alpha-beta/biosynthesis , Receptors, Antigen, T-Cell, alpha-beta/genetics , Receptors, Antigen, T-Cell, alpha-beta/isolation & purification , Reverse Transcriptase Polymerase Chain Reaction , Sequence Analysis, DNA , Skin Neoplasms/immunology , Skin Neoplasms/metabolism , T-Lymphocyte Subsets/metabolism , Transcription, Genetic/immunology
11.
Oncogene ; 18(9): 1777-80, 1999 Mar 04.
Article in English | MEDLINE | ID: mdl-10208439

ABSTRACT

Mutations in LKB1/STK11, a gene mapping to chromosome 19p13.3 and encoding a widely expressed serine/threonine kinase, were recently identified as the cause of Peutz-Jeghers syndrome. Despite the hamartomatous polyps and increased cancer risk associated with this syndrome, somatic alterations in LKB1/STK11 have not been identified in human tumours. Prompted by another feature of the syndrome, lentigines of the lips and oral mucosa, we evaluated the status of LKB1/STK11 expression, deletion, and mutation in cell lines and tumour samples from 35 patients with sporadic malignant melanoma. Two somatic mutations were identified, a nonsense mutation (Glu170Stop) causing exon skipping and intron retention, and a missense mutation (Asp194Tyr) affecting an invariant residue in the catalytic subunit of LKB1/STK11. Our data suggest that LKB1/STK11 may contribute to tumorigenesis in a small fraction of malignant melanomas.


Subject(s)
Mutation , Peutz-Jeghers Syndrome/enzymology , Peutz-Jeghers Syndrome/genetics , Protein Serine-Threonine Kinases/genetics , AMP-Activated Protein Kinase Kinases , Humans , Melanoma , Tumor Cells, Cultured
12.
Biotechniques ; 25(2): 244-50, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9714884

ABSTRACT

Accumulation of T cells carrying identical T-cell receptors (TCR) is associated with a number of immunological and non-immunological diseases. Therefore, it is of interest to be able to analyze complex T-cell populations for the presence of clonally expanded subpopulations. Here, we describe a simple method combining reverse transcription (RT)-PCR and denaturing gradient gel electrophoresis (DGGE) for rapid detection and characterization of T-cell clonality. The detection of clonally expanded T cells by DGGE relies on the fact that clonal transcripts have no junctional diversity and therefore resolve at a fixed position in the gel, which is determined by their melting properties. For polyclonal populations with a high degree of junctional diversity, the different DNA molecules will resolve at different positions in the gel and together will be revealed as a smear. For each of the TCR beta-variable gene (BV) 1-24 families, cloned transcripts were amplified and shown to resolve as distinct bands in the denaturing gradient gel, whereas the analysis of polyclonal T-cell populations resulted in a smear in the gel. The present method might prove useful to test for clonotypic T-cells in a variety of pathological and physiological conditions and for monitoring T-cell responses in diagnostic and therapeutic settings.


Subject(s)
Electrophoresis, Polyacrylamide Gel/methods , Nucleic Acid Denaturation , Receptors, Antigen, T-Cell, alpha-beta/genetics , T-Lymphocytes/metabolism , Cells, Cultured , Clone Cells , DNA Primers , Humans , Receptors, Antigen, T-Cell, alpha-beta/chemistry , Reverse Transcriptase Polymerase Chain Reaction , Transcription, Genetic
13.
Proc Natl Acad Sci U S A ; 95(15): 8785-90, 1998 Jul 21.
Article in English | MEDLINE | ID: mdl-9671756

ABSTRACT

The induction of an immunological antitumor response capable of eradicating metastatic tumors is the ultimate goal of immunotherapy. We have recently shown that this can be achieved by interleukin 2 (IL-2) therapy directed to the tumor microenvironment by a recombinant antibody-IL-2 fusion protein. It is not known, however, whether this curative treatment is associated with a predominance of T cells carrying specific T cell receptor variable beta regions (TCRBV) or the presence of clonally expanded T cells. To address this question, we have used a quantitative reverse transcriptase-coupled PCR method to analyze the TCRBV region repertoire in tumor-infiltrating lymphocytes of treated and untreated animals. As controls the TCRBV region repertoire was analyzed in blood and skin from disease-free animals. The results indicate an overexpression of TCRBV5 in the tumors of all treated mice and an additional overexpression of individual regions in each tumor. Direct sequencing of these TCRBV regions did not reveal any evidence of clonal expansions. However, since clonal expansions could exist as subpopulations in highly expressed regions, not detectable by direct sequencing, a denaturing gradient gel electrophoresis assay was used for clonal analysis of TCRBV PCR products. Denaturing gradient gel electrophoresis analysis of selected TCRBV regions revealed the presence of clonotypic T cells in tumors from both treated and untreated animals. These data indicate that targeted IL-2 therapy in this model does not induce clonal T cell responses de novo, rather it acts as an activator for an already existing population of clonotypic T cells.


Subject(s)
Interleukin-2/pharmacology , Lymphocyte Activation , Melanoma, Experimental/immunology , T-Lymphocytes/immunology , Animals , Base Sequence , Clone Cells/immunology , DNA Primers , Electrophoresis, Polyacrylamide Gel , Humans , Melanoma, Experimental/pathology , Mice , Mice, Inbred C57BL , Polymerase Chain Reaction , Tumor Cells, Cultured
14.
Br J Dermatol ; 138(1): 3-12, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9536217

ABSTRACT

The genes encoding the T-cell receptor (TCR) variable beta (TCRBV) regions were studied in skin biopsy samples from 24 patients with cutaneous T-cell lymphomas (CTCL), i.e. mycosis fungoides (n = 7), Sézary syndrome (n = 4), lymphomatoid papulosis (n = 3) and large cell CTCL with (n = 3) or without (n = 7) CD30 expression. A panel of 24 primers specific for TCRBV families 1-24 was designed and applied to cDNA using a semiquantitative reverse transcriptase coupled polymerase chain reaction (PCR) method. Three patients showed restricted expression of a limited number (1-3) of TCRBV families. In the remaining patients, an average of 17 (range: 13-22) different families was expressed. All patients showed elevated (> 10%) expression of individual families significantly higher than that seen in normal blood lymphocytes, but no preferential usage of particular gene families was observed. Direct sequence analysis of more than 60 PCR products revealed clonal TCR transcripts in 18 patients. A single T-cell clone, constituting 9-100% (mean: 26%) of the TCRBV mRNA, was present in 12 patients; two T-cell clones, constituting 13-72% (mean: 21.5%) of the TCRBV mRNA, were present in five patients; and three T-cell clones, accounting for < 0.5-13% of the TCRBV mRNA, were present in one patient. In the remaining six patients, clonal TCR transcripts could not be identified. It is concluded that most CTCL contain both clonal and non-clonal (reactive) T cells, and that the latter cells are more numerous than anticipated. These cells may be engaged in tumour immune reactions, although prospective studies and/or serial investigations are needed to elucidate this issue fully.


Subject(s)
Genes, T-Cell Receptor beta , Immunoglobulin Variable Region/genetics , Lymphoma, T-Cell, Cutaneous/genetics , Skin Neoplasms/genetics , Adult , Aged , Aged, 80 and over , Blotting, Southern , DNA Primers , Female , Gene Expression , Genes, T-Cell Receptor alpha , Humans , Lymphocytes/immunology , Lymphoma, T-Cell, Cutaneous/immunology , Male , Middle Aged , Polymerase Chain Reaction , Receptors, Antigen, T-Cell, alpha-beta/metabolism , Retrospective Studies , Skin Neoplasms/immunology
15.
Int J Cancer ; 70(5): 582-6, 1997 Mar 04.
Article in English | MEDLINE | ID: mdl-9052759

ABSTRACT

TAP1 and TAP2 molecules are involved in the transport of peptides prior to their association with class I molecules and are mandatory for efficient antigen presentation. To investigate whether loss of expression of TAP1 or TAP2 is a likely mechanism of immune escape in malignant melanoma, TAP1 and TAP2 mRNA was analyzed by RT-PCR in 39 melanoma cell lines expressing at least 2 of the known melanoma-associated antigens, tyrosinase, Melan-A/MART-1, gp100, MAGE-1 and MAGE-3. All 39 cell lines expressed both TAP1 and TAP2 at the mRNA level. To investigate other factors potentially involved in immune escape, the expression of LMP2, LMP7, HLA class I molecules, beta2-microglobulin (beta2m) and specific HLA-A alleles was evaluated by RT-PCR and FACS analyses. All 39 cell lines expressed LMP2, LMP7 and beta2m. A single cell line (FM37) had lost the expression of class I molecules, and this same cell line showed loss of expression of the HLA-A2 heavy chain. No cell lines showed loss of expression of the HLA-A1 heavy chain. Based on our studies of in vitro established cell lines, loss of TAP1/2 or LMP2/7 expression does not appear to be a common mechanism of immune escape in malignant melanoma.


Subject(s)
ATP-Binding Cassette Transporters/metabolism , Amino Acid Transport Systems , Exoribonucleases , Fungal Proteins/metabolism , Melanoma/metabolism , Neoplasm Proteins/metabolism , Trans-Activators/metabolism , ATP Binding Cassette Transporter, Subfamily B, Member 3 , ATP-Binding Cassette Transporters/genetics , Antigens, Neoplasm/metabolism , Fungal Proteins/genetics , Histocompatibility Antigens Class I/metabolism , Humans , Neoplasm Proteins/genetics , Polymerase Chain Reaction , RNA, Messenger/metabolism , Saccharomyces cerevisiae Proteins , Trans-Activators/genetics , Tumor Cells, Cultured
16.
J Clin Invest ; 98(2): 279-84, 1996 Jul 15.
Article in English | MEDLINE | ID: mdl-8755635

ABSTRACT

The T cell receptor (TCR) BV variable (V) gene repertoire of tumor infiltrating lymphocytes (TIL) found in progressive and regressive regions of the same primary human melanomas were characterized by reverse transcription coupled polymerase chain reaction (RT-PCR). After surgery, the tumors were divided into different parts which were judged as regressive or progressive regions by visual inspection. Subsequently this diagnosis was confirmed by histology. From a total of four primary melanomas analyzed, 2 were drawn to be HLA-A2+. Only relatively few BV-gene families were expressed at significant levels in each of the samples. Comparison of the BV-expression in regressive versus progressive regions of the same tumor revealed major differences in all cases examined. Direct sequencing of RT-PCR products indicated that highly expressed BV-gene families were of clonal origin in both the regressive and progressive regions. Together, these data strongly suggest the occurrence of clonal T cell responses in both regressive and progressive areas of the same primary tumor. The differences in expression of certain BV-genes may correlate with the functional activity of certain populations of tumor-infiltrating T cells.


Subject(s)
Clonal Anergy , Lymphocytes, Tumor-Infiltrating/immunology , Melanoma/immunology , Melanoma/pathology , T-Lymphocytes/immunology , Amino Acid Sequence , Base Sequence , Blotting, Southern , DNA Primers , Disease Progression , HLA-A2 Antigen/genetics , Humans , Lymphocytes, Tumor-Infiltrating/pathology , Melanoma/genetics , Molecular Sequence Data , Polymerase Chain Reaction , Receptors, Antigen, T-Cell, alpha-beta/genetics
17.
Scand J Work Environ Health ; 17(6): 436-40, 1991 Dec.
Article in English | MEDLINE | ID: mdl-1788537

ABSTRACT

Aflatoxin B1 is suspected as an etiologic factor in the increased risk for primary liver cancer among workers in animal-feed processing plants in Denmark. Aflatoxin bound to serum albumin was therefore measured for feed-processing workers. Blood samples were collected immediately after vacation and after four weeks of work, and aflatoxin was quantified by competitive enzyme-linked immunosorbant assay. Seven of 45 individuals with an estimated exposure of 64 ng aflatoxin B1.d-1.kg-1 body weight were positive. Three positive workers had been unloading a cargo with an aflatoxin B1 level of 26 micrograms.kg-1 raw material. The exposure level correlated well with the job titles. Dust samples collected at different sites showed considerable variation in the amount of aflatoxin B1 (nondetectable to 8 micrograms.kg-1 dust). The exposure to aflatoxin B1 may only partially explain the increased risk of liver cancer.


Subject(s)
Aflatoxin B1/pharmacokinetics , Animal Feed , Dust , Occupational Exposure , Adult , Aflatoxin B1/adverse effects , Animal Feed/analysis , DNA Damage , Dust/adverse effects , Dust/analysis , Enzyme-Linked Immunosorbent Assay , Humans , Male , Middle Aged , Protein Binding
18.
Arch Environ Health ; 45(1): 31-4, 1990.
Article in English | MEDLINE | ID: mdl-1690532

ABSTRACT

Antibody activity against an aflatoxin epitope has been detected in serum from individuals who live in Kenya and who experience high exposure to aflatoxin B1. The activity was higher than in Danish people. The highest antibody activity was found in individuals who were recently exposed to aflatoxin B1. The ratio between IgG and IgM activities was higher in individuals with a high antibody titer. The specificity of the antibody activity differed in the serums obtained from Danish and Kenyan persons ("Danish" and "Kenyan" serum, respectively). The activity in Danish serum was inhibited by an aflatoxin-like substance isolated from human urine, whereas aflatoxin B1 did not inhibit the activity. In contrast, the activity in Kenyan serum was not inhibited by the aflatoxin-like substances. Therefore, the presence of antibodies against aflatoxin in humans indicates exposure to aflatoxin or aflatoxin-antigenic material. However, the biological consequences of these antibodies remain unknown.


Subject(s)
Aflatoxins/immunology , Antibodies/analysis , Carcinogens , Epitopes/analysis , Aflatoxin B1 , Antibody Specificity , Denmark , Environmental Exposure , Enzyme-Linked Immunosorbent Assay , Humans , Immunoglobulin G/analysis , Kenya
19.
Cancer Res ; 47(13): 3430-3, 1987 Jul 01.
Article in English | MEDLINE | ID: mdl-3034416

ABSTRACT

Two major etiological agents, hepatitis B virus and aflatoxin B1, are considered to be involved in the induction of liver cancer in Africa. In order to elucidate any synergistic effect of these two agents we conducted a study in various parts of Kenya with different liver cancer incidence in order to establish the rate of exposure to aflatoxin and the prevalence of hepatitis infections. Of all tested individuals 12.6% were positive for aflatoxin exposure as indicated by the urinary excretion of aflatoxin B1-guanine. Assuming no annual and seasonal variation, a regional variation in the exposure was observed. The highest rate of aflatoxin exposure was found in the Western Highlands and Central Province. The incidence of hepatitis infection nationwide as measured by the presence of the surface antigens was 10.6%, but a wide regional variation was observed. A multiplicative and additive regression analysis to investigate if hepatitis and aflatoxin exposure had a synergetic effect in the induction of liver cancer was negative. However, a moderate degree of correlation between the exposure to aflatoxin and liver cancer was observed when the study was limited to certain ethnic groups. The study gives additional support to the hypothesis that aflatoxin is a human liver carcinogen.


Subject(s)
Aflatoxins/urine , Carcinoma, Hepatocellular/etiology , DNA Damage , Guanine/analogs & derivatives , Hepatitis B/complications , Liver Neoplasms/etiology , Aflatoxin B1 , Carcinoma, Hepatocellular/epidemiology , Female , Guanine/urine , Hepatitis B Surface Antigens/analysis , Humans , Kenya , Liver Neoplasms/epidemiology , Male , Sex Factors
20.
Chem Biol Interact ; 60(2): 217-26, 1986 Nov.
Article in English | MEDLINE | ID: mdl-3791489

ABSTRACT

A benzo[a]pyrene(BP)-Gua adduct was extracted in the urine of rats treated with BP. Some (0.15%) of the administered dose of BP was excreted as BP-Gua within 48 h. A double labelling experiment demonstrated that the excreted product contained both a BP and a Gua moiety. Partially hepatectomized rats treated with [14C]Gua during the regenerative phase were injected with [3H]BP and the urine collected and processed by chromatographic procedures. The adduct had similar chromatographic properties to the adduct released from human PLC/5 cells treated with 7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene (BPDE) and co-chromatographed with 7-BPDE-Gua released from BPDE-adducted DNA under aqueous conditions. Detection and quantitation of BP-Gua offers an alternative, non-invasive method of monitoring individuals exposed to carcinogenic polycyclic aromatic hydrocarbons (PAHs).


Subject(s)
Benzo(a)pyrene/pharmacology , Benzopyrenes/urine , Guanine/analogs & derivatives , Animals , Benzopyrenes/metabolism , Cell Line , Guanine/metabolism , Guanine/urine , Humans , Liver Neoplasms/metabolism , Male , Rats , Rats, Inbred Strains , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...